Cosmos Health Inc. (NASDAQ: COSM) announced it has received its first orders for C-ScrubVet, a new veterinary antimicrobial line. Sales have commenced in the United Kingdom, marking the company's entry into the $69 billion global animal health market.

The product, formulated for dogs, cats, horses, and large animals, is supplied in a 500ml pump-dispenser bottle. It contains 4% chlorhexidine digluconate and is certified under European standards EN 1656 and EN 1657 for bactericidal and fungicidal activity. The launch extends the company's established C-Scrub franchise beyond human healthcare into adjacent categories.

Manufacturing and Regulatory Compliance

C-ScrubVet is manufactured in-house at Cana Laboratories, the company's EU GMP-licensed and EMA-certified facility in Athens. This vertical integration allows Cosmos Health to leverage existing quality and regulatory infrastructure shared across the wider C-Scrub range. The formulation builds on the company's existing C-Scrub Wash 4% platform, which is already established in e-commerce, retail, and hospital settings following EN 12791 certification in April 2026.

Distribution Strategy

The company is pursuing a phased, multi-channel rollout beginning with an e-commerce-led launch in the UK. This approach aims to provide immediate market access and early visibility on demand. Planned expansion into pet store chains, veterinary practices, and clinics is intended to convert early traction into recurring distribution. Additional European markets are targeted from Q4 2026.

Financial Context and Guidance

The veterinary launch adds a new growth channel to Cosmos Health's core pharmaceutical and nutraceutical business. The core business delivered record fiscal year 2025 revenue of $65.27 million, up 20% year-over-year, and continued double-digit revenue growth in the first half of 2026.

C-ScrubVet is expected to be one of several catalysts supporting the company's previously issued 2029 guidance. The guidance targets $200.6 million in revenue, $44.2 million in adjusted EBITDA, and $31.0 million in net income.

What the Numbers Show

The 2029 revenue guidance of $200.6 million represents more than a threefold increase from the record FY25 revenue of $65.27 million. This implies that new growth channels, such as the veterinary segment, alongside continued expansion in core businesses, must contribute significantly to bridge the gap between current performance and long-term targets.

Cosmos Health Inc. (NASDAQ: COSM) delivered record revenue in its second quarter of 2026, reaching $18.99 million, a 28.8% increase year-on-year. The company also retired an $8 million senior secured convertible note twelve months ahead of maturity, eliminating further dilution risk.

The healthcare group posted first-half revenue of $36.91 million, up 29.7% from the prior period. Management highlighted a strengthened balance sheet with total liabilities declining 13.3% to $40.79 million as of June 30, 2026, while stockholders' equity rose 12.2% to $20.67 million.

Financial Performance

Cosmos Health achieved its highest quarterly revenue figures across all reporting periods in 2026, building on a record FY2025 performance.

Adjusted EBITDA improved to a loss of $1.13 million in Q2 2026, narrowing from the prior period. Operating cash requirements fell more than 30% below the average of the previous two years, driven by revenue growth and cost reduction initiatives.

What the Numbers Show

The divergence between revenue growth and liability reduction signals a deliberate deleveraging strategy. While revenue grew nearly 30% in H1 2026, total liabilities dropped by $6.27 million. This simultaneous expansion of top-line sales and contraction of debt obligations improved the liabilities-to-assets ratio by 550 basis points to 66.4%, suggesting management is prioritizing balance sheet stability alongside commercial scaling.

Capital Structure and Shareholder Returns

Cosmos Health simplified its capital structure by withdrawing its Form S-1 and Form S-3 registration statements, meaning no shelf registration or ATM offering program is currently active. The company repaid the $8 million ATW convertible note on August 28, 2026, avoiding potential dilution.

Additionally, 4,874,126 Series B warrants expired unexercised in May 2026, removing approximately 38% of the warrant overhang. Under its $5 million share repurchase authorization, the company bought back 5.11 million shares for roughly $1.11 million.

Operational Highlights

Growth was broad-based across divisions:

• CosmoFarm: Added 80+ pharmacies, achieving a $60 million annualized run-rate.
• Cana Laboratories: Orderbook reached an all-time high of 25 million+ units, supported by multi-year agreements with clients like Verisfield and Pharmex.
• Decahedron: Nearly doubled UK revenue year-on-year in Q2 2026.
• 18 Series / NOOR: Launched Cur18, Liv18, Oliv18, and Fort18 in the US, projecting combined annualized revenue exceeding $22.7 million at gross margins above 70%.

Strategic Expansion

Cosmos Health secured major distribution deals, including an exclusive five-year agreement with Innova Healthcare in Saudi Arabia for Sky Premium Life, with an initial purchase order of 126,000 units. In the UK, C-Scrub gained listings at Tesco and Superdrug, while also entering hospital channels following EN 12791 certification.

The company filed international patent applications for CCX0722 hydrogel in the US, Europe, Australia, and Canada. It also identified approximately $20 million in non-core assets, including real estate and digital holdings, for potential monetization.